EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the 'Rebiopsy on osi' Study).
Large real-world study reveals which genetic changes predict resistance to osimertinib, guiding doctors toward more effective second-line treatments.
The 'Rebiopsy on osi' study is one of the largest real-world Italian multicenter analyses of molecular resistance profiling in EGFR-mutant NSCLC at first-line osimertinib progression, characterizing acquired mutations such as C797S, MET amplification, and others. The study links rebiopsy findings to second-line therapy outcomes, providing clinically actionable guidance for the growing patient population requiring treatment beyond osimertinib.
What the study was
- Study design
- Multicenter retrospective real-world cohort
- Population
- EGFR-mutant NSCLC patients progressing on first-line osimertinib, Italian multicenter cohort
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- The oncologist
Why it surfaced
Post-osimertinib progression management is one of the most clinically urgent problems in thoracic oncology. Multicenter real-world rebiopsy data from 50 Italian centers provides immediately actionable information on resistance mechanisms and second-line therapy selection.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.